Platelet Glycoprotein Iib/iiia Inhibitors In Cardiovascular Disease (contemporary Cardiology)

A. Michael Lincoff takes advantage of critically important new knowledge arising from recent clinical trials to update and expand his acclaimed Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. This substantially enhanced Second Edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes, on outcomes with chronic oral GPIIb/IIIa blockade following acute coronary syndromes, and on fibrinolytic therapy during acute myocardial infarctions. Additional enhancements include revised findings from the latest trials of GPIIb/IIIa inhibition during percutaneous coronary intervention, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. The book also explains the scientific basis of this therapy, evaluates its benefits and risks for patients, and summarizes detailed data from its various clinical trials. Comprehensive and definitive, Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, Second Edition offers physicians, cardiologists, emergency room doctors, and basic scientists a complete and authoritative review of the state-of-the-art in glycoprotein IIb/IIIa receptor inhibitor use today.

This substantially revised second edition contains new chapters on the role of GPIIb/IIIa blockade during acute coronary syndromes or with fibrinolytic therapy during acute myocardial infarctions, and updated and expanded information on the latest trials of GP IIb/IIIa inhibition during percutaneous coronary intervention. Additional improvements include a new chapter on outcomes with chronic oral GP IIb/IIIa blockade following acute coronary syndromes, discussion of GPIIb/IIIa blockade with other platelet and thrombin inhibitors, and a review of the potential effects beyond inhibition of platelet aggregation. Platelet Glycoprotein IIb/IIIa inhibitors in Cardiovascular Disease, Second Edition offers today's physicians, cardiologists, emergency room doctors, and basic scientists the most complete and authoritative review of the state-of-the-art in glycoprotein Iib/IIIa receptor inhibitor use.

The book contains black-and-white illustrations.

This book provides a definitive basis of knowledge of the use of glycoprotein IIb/IIIa inhibitors for the treatment of cardiac diseases and for the prevention of ischemic complications after percutaneous coronary intervention. The first section concentrates on the basic pathophysiology underlying the theoretical usefulness and development of this class of agents. It covers the role of thrombosis and platelet activity as well as cell surface adhesion molecules. The second section concentrates on the GP IIb/IIIa blockade following percutaneous coronary revascularization. Three agents are reviewed for this indication (abciximab, Integrilin, and tirofiban) with a focus on the data derived from the major Phase III trials. This section concludes with a key summary integrating the results of the major trials of GP IIb/IIIa during coronary intervention, comparing and contrasting the different agents, and providing practical guidelines for clinical use. The third section focuses on the emerging indication of GP IIb/IIIa blockade during the acute coronary ischemic syndromes, unstable angina and acute myocardial infarction, discussing the major Phase II trials and ongoing studies in the filed. The fourth and final section provides a vision of the future development and application of these agents for the treatment of vascular disease including the new frontier of chronic antiplatelet therapy with oral GP IIb/IIIa agents and the potential role of these agents in non-coronary (peripheral and cerebral) vascular disease.

Front Matter....Pages i-x Front Matter....Pages 1-1 Thrombosis in Acute Coronary Syndromes and Coronary Interventions....Pages 3-21 Platelet Adhesion....Pages 23-37 Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis....Pages 39-71 Glycoprotein IIb/IIIa Antagonists....Pages 73-101 Front Matter....Pages 103-103 Abciximab During Percutaneous Coronary Intervention....Pages 105-124 Eptifibatide in Coronary Intervention....Pages 125-146 Tirofiban in Interventional Cardiology....Pages 147-166 Overview of the Glycoprotein IIb/IIIa Interventional Trials....Pages 167-199 Front Matter....Pages 201-201 The Use of Abciximab in Therapy-Resistant Unstable Angina....Pages 203-231 Unstable Angina Trials....Pages 233-262 Platelet Glycoprotein IIb/IIIa Inhibitors and an Invasive Strategy....Pages 263-273 Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction....Pages 275-287 Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction....Pages 289-302 Front Matter....Pages 303-303 Economics of Glycoprotein IIb/IIIa Inhibition....Pages 305-319 Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents....Pages 321-340 Platelet Glycoprotein IIb/IIIa Antagonists....Pages 341-364 Oral Agents....Pages 365-382 Platelet Glycoprotein IIb/IIIa Inhibitors....Pages 383-396 Cerebrovascular Interventions....Pages 397-407 Cerebrovascular Aspects of Glycoprotein IIb/IIIa Receptor Inhibitors....Pages 409-423 Front Matter....Pages 303-303 Evolution of Drug Development in Evidence-Based Medicine....Pages 425-458 Back Matter....Pages 459-476